[Featured Stock] Daewon Pharmaceutical Soars 27% on Study Showing Cholesterol Drug's Effect Against COVID-19

[Asia Economy Reporter Ji Yeon-jin] European researchers have announced a study result showing that the drug 'Fenofibrate,' used as a treatment for hyperlipidemia, can reduce infection of the novel coronavirus disease (COVID-19) by up to 70%. Following this, Daewon Pharmaceutical, which manufactures hyperlipidemia treatment drugs containing this ingredient, is showing strong performance.

Daewon Pharmaceutical is trading at 20,300 KRW, up 27.19% (4,400 KRW) compared to the previous day as of 10 a.m. on the 9th in the KOSPI market.

According to research published recently in the international academic journal 'Frontiers in Pharmacology,' the hyperlipidemia treatment drug 'Fenofibrate' is known to inhibit the binding of the COVID-19 virus to the ACE2 protein in the human body. The research team tested the efficacy of this drug through cell experiments, and the results showed that Fenofibrate reduced COVID-19 virus infection by up to 70%. Dr. Fahad Khanhim of the University of Birmingham in the UK stated, "While vaccines are necessary to prevent the spread of the virus, it is essential to secure a variety of drugs to treat COVID-19 patients."

Daewon Pharmaceutical developed TG Pheon, the world's first tablet form of fenofibrate choline formulation, and ranks second in fibrate prescriptions. It has achieved good results, including surpassing 10 billion KRW in prescription sales in the fibrate market.

This content was produced with the assistance of AI translation services.